在小细胞肺癌中推进治疗方法
Anish Thomas1, Chirayu Mohindroo2, Giuseppe Giaccone3
1Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. anish.thomas@nih.gov.
小细胞肺癌 (SCLC) 由于早期转移和耐药性,仍然具有挑战性. 对瘤生物学和向蛋白质的新见解为改变SCLC疗法和改善患者治疗结果提供了希望.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 翻译医学是一种翻译医学.
背景情况:
- 小细胞肺癌 (SCLC) 占肺癌病例的10-15%.
- SCLC是由快速进展,早期转移和对治疗的耐药性定义的.
- 目前的SCLC疗法,主要是化疗和免疫检查点抑制剂,提供有限的生存益处.
研究的目的:
- 审查最近在SCLC生物学方面的进展.
- 突出治疗创新和SCLC生物标志物开发.
- 讨论优化SCLC治疗和克服耐药性的战略.
主要方法:
- 最近的SCLC研究的文献综述.
- 对新型治疗点和生物标志物的分析.
- 在SCLC治疗优化中讨论反转化原理.
主要成果:
- 了解SCLC瘤异质性的进展至关重要.
- 鉴定可向的细胞表面蛋白质为治疗提供了新的途径.
- 免疫检查点抑制剂在SCLC中提供了适度的生存改善.
结论:
- 对SCLC生物学和可向蛋白质的新见解可以改变治疗模式.
- 克服治疗耐药性和确保公平获取是未来的关键方向.
- 反向翻译对于改进SCLC疗法和改善患者护理至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
